Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review

The optimal dose of recombinant tissue plasminogen activator (rtPA) for acute ischaemic stroke (AIS) remains controversial, especially in Asian countries. We aimed to update the evidence regarding the use of low-dose versus standard-dose rtPA. We performed a systematic literature search across MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) from inception to 22 August 2016 to identify all related studies. The outcomes were death or disability (defined by modified Rankin Scale 2–6), death, and symptomatic intracerebral haemorrhage (sICH). Where possible, data were pooled for meta-analysis with ORs and corresponding 95% CIs by means of random-effects or fixed-effects meta-analysis. We included 26 observational studies and 1 randomised controlled trial with a total of 23 210 patients. Variable doses of rtPA were used for thrombolysis of AIS in Asia. Meta-analysis shows that low-dose rtPA was not associated with increased risk of death or disability (OR 1.13, 95% CI 0.95 to 1.33), or death (OR 0.86, 95% CI 0.74 to 1.01), or decreased risk of sICH (OR 1.06, 95% CI 0.65 to 1.72). The results remained consistent when sensitivity analyses were performed including only low-dose and standard-dose rtPA or only Asian studies. Our review shows small difference between the outcomes or the risk profile in the studies using low-dose and/or standard-dose rtPA for AIS. Low-dose rtPA was not associated with lower risk of death or disability, death alone, or sICH.

[1]  Mark Woodward,et al.  Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. , 2016, The New England journal of medicine.

[2]  Eric E. Smith,et al.  Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2016, Stroke.

[3]  P. Gorelick,et al.  Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study , 2015, Stroke.

[4]  M. Woodward,et al.  Statistical analysis plan for evaluating low‐ vs. standard‐dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED) , 2015, International journal of stroke : official journal of the International Stroke Society.

[5]  M. Woodward,et al.  Rationale, Design, and Progress of the ENhanced Control of Hypertension ANd Thrombolysis Stroke Study (ENCHANTED) Trial: An International Multicenter 2 × 2 Quasi-Factorial Randomized Controlled Trial of Low- vs. Standard-Dose rt-PA and Early Intensive vs. Guideline-Recommended Blood Pressure Lowerin , 2015, International journal of stroke : official journal of the International Stroke Society.

[6]  M. Koga,et al.  Acute reperfusion therapy and stroke care in Asia after successful endovascular trials. , 2015, Stroke.

[7]  Yongjun Wang,et al.  Thrombolysis for Acute Ischaemic Stroke with Alteplase in an Asian Population: Results of the Multicenter, Multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW) , 2014, International journal of stroke : official journal of the International Stroke Society.

[8]  Yilong Wang,et al.  Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Stroke Is Better Than Low Doses , 2014, Stroke.

[9]  J. Jeng,et al.  Different Doses of Recombinant Tissue-Type Plasminogen Activator for Acute Stroke in Chinese Patients , 2014, Stroke.

[10]  T. Ochi,et al.  The Safety and Effectiveness of Low-Dose Recombinant Tissue Plasminogen Activator (0.6 mg/kg) Therapy for Elderly Acute Ischemic Stroke Patients (≥ 80 Years Old) in the Pre-endovascular Era , 2014, Neurologia medico-chirurgica.

[11]  V. Sharma,et al.  Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator , 2013, Expert review of neurotherapeutics.

[12]  Shuming Pan,et al.  Efficacy and safety of a modified intravenous recombinant tissue plasminogen activator regimen in Chinese patients with acute ischemic stroke. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[13]  E. Mori,et al.  Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[14]  M. Sun,et al.  Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose , 2012, Journal of thrombosis and haemostasis : JTH.

[15]  K. Kario,et al.  Low-Dose Intravenous Recombinant Tissue-Type Plasminogen Activator Therapy for Patients With Stroke Outside European Indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry , 2012, Stroke.

[16]  N. Venketasubramanian,et al.  Current Status of Intravenous Thrombolysis for Acute Ischemic Stroke in Asia , 2011, International journal of stroke : official journal of the International Stroke Society.

[17]  G. Guyatt,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[18]  H. Leung,et al.  An expedited stroke triage pathway: the key to shortening the door-to-needle time in delivery of thrombolysis. , 2010, Hong Kong medical journal = Xianggang yi xue za zhi.

[19]  V. Sharma,et al.  Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. , 2010, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[20]  Y. Shinohara,et al.  Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS) , 2010, Stroke.

[21]  A. L. T. Truong,et al.  Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry , 2010, European journal of neurology.

[22]  S. Davis,et al.  Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke , 2010, Journal of Clinical Neuroscience.

[23]  Chung-Hsiang Liu,et al.  Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients: The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study , 2010, Stroke.

[24]  R. Borgohain,et al.  Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India. , 2010, Neurology India.

[25]  M. Wasay,et al.  Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan , 2010, Neurological Sciences.

[26]  E. Mori,et al.  Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion: Japan Alteplase Clinical Trial II (J-ACT II) , 2010, Stroke.

[27]  K. Kario,et al.  Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients: General Outcomes and Prognostic Factors From the SAMURAI Register , 2009, Stroke.

[28]  M. Noone,et al.  Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008 , 2009, Journal of Clinical Neuroscience.

[29]  S. Sung,et al.  Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. , 2009, Acta neurologica Taiwanica.

[30]  S. R. Sharma,et al.  Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective , 2008, Annals of Indian Academy of Neurology.

[31]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[32]  M. Matsushita,et al.  Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit , 2007, Clinical Neurology and Neurosurgery.

[33]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[34]  N. Suwanwela,et al.  Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation , 2006, Clinical Neurology and Neurosurgery.

[35]  Y. Shinohara,et al.  Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) , 2006, Stroke.

[36]  A. Alexandrov,et al.  Safety and Feasibility of a Lower Dose Intravenous TPA Therapy for Ischemic Stroke beyond the First Three Hours , 2005, Cerebrovascular Diseases.

[37]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[38]  O. Matsuo,et al.  The Differences in Thrombolytic Effects of Administrated Recombinant t-PA between Japanese and Caucasians , 2002, Thrombosis and Haemostasis.

[39]  A. Alexandrov,et al.  Speed of Intracranial Clot Lysis With Intravenous Tissue Plasminogen Activator Therapy: Sonographic Classification and Short-Term Improvement , 2001, Circulation.

[40]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[41]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[42]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[43]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[44]  P. Couturier.  Japan , 1988, The Lancet.

[45]  R. Joynt.  Department , 1960, Neurology.

[46]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[47]  S. Muengtaweepongsa,et al.  Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[48]  M. Tripathi,et al.  Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. , 2007, Neurology India.

[49]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. , 2000, JAMA.

[50]  P Trouillas,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.